Loading…
Swisschems was selling unapproved drugs—specifically Semaglutide and Retatrutide—through its website and social media platforms in violation of the Federal Food, Drug, and Cosmetic Act. Despite labeling the products as "research chemicals only," the company made disease treatment and body function claims (including references to weight regulation, metabolic effects, and cardiovascular outcomes in diabetic patients) that established these products as drugs intended for human use. The FDA identified that Swisschems was introducing these unapproved new drugs into interstate commerce without required FDA approval, and was directing consumers to purchase them through multiple online channels including Facebook and Instagram.